COPENHAGEN, Denmark, Aug. 8, 2023 /PRNewswire/ -- Bactolife A/S ("Bactolife"), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that it has successfully raised EUR >30 million since its April 2021 seed round.
Read more at prnewswire.comPress Releases
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.